Rein Therapeutics publishes LTI-03 presentation, Phase 2 trial enrolling
Rein Therapeutics published an LTI-03 presentation citing Phase 1b biomarker activity, preclinical antifibrotic data and that the RENEW Phase 2 trial is now enrolling.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.